ArticleThe Journal of molecular diagnostics : JMD2018
OncoKids: A Comprehensive Next-Generation Sequencing Panel for Pediatric Malignancies.
Article in The Journal of molecular diagnostics : JMD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of theNeuro-oncology pediatrics · 2026Article
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution.Virchows Archiv : an international journal of pathology · 2025Article
- Retinoblastoma: Molecular Evaluation of Tumor Samples, Aqueous Humor, and Peripheral Blood Using a Next-Generation Sequence Panel.International journal of molecular sciences · 2025Article
- Article
- SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Pediatric Chordoma: A Tale of Two Genomes.Molecular cancer research : MCR · 2024Article
- Development of second genetically distinct T-lymphoblastic leukemia in a pediatric patient.Pediatric blood & cancer · 2024Article
- IKZF1Pediatric blood & cancer · 2024Article
- Histone H3 trimethylation on lysine 27 immunostaining pattern inTranslational pediatrics · 2024Article
- Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion.Acta neuropathologica communications · 2024Article
- Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.The Journal of molecular diagnostics : JMD · 2024Article
- Venetoclax and Azacitidine in the Treatment ofJCO precision oncology · 2023Review
- Utilization of Genomic Tumor Profiling in Pediatric Liquid Tumors: A Clinical Series.Hematology reports · 2023Article
- Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors.NPJ precision oncology · 2023Article
- Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.Cancer science · 2022Article
- Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.Neuro-oncology · 2022Article
- Characterization of PAX5 intragenic tandem multiplication in pediatric B-lymphoblastic leukemia by optical genome mapping.Blood advances · 2022Article
- Advanced Molecular Characterisation in Relapsed and Refractory Paediatric Acute Leukaemia, the Key for Personalised Medicine.Journal of personalized medicine · 2022Article
- Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.Journal of cancer research and clinical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
The OncoKids panel is an amplification-based next-generation sequencing assay designed to detect diagnostic, prognostic, and therapeutic markers across the spectrum of pediatric malignancies, including leukemias, sarcomas, brain tumors, and embryonal tumors. This panel uses low input amounts of DNA (20 ng) and RNA (20 ng) and is compatible with formalin-fixed, paraffin-embedded and frozen tissue, bone marrow, and peripheral blood. The DNA content of this panel covers the full coding regions of 44 cancer predisposition loci, tumor suppressor genes, and oncogenes; hotspots for mutations in 82 genes; and amplification events in 24 genes. The RNA content includes 1421 targeted gene fusions. We describe the validation of this panel by using a large cohort of 192 unique clinical samples that included a wide range of tumor types and alterations. Robust performance was observed for analytical sensitivity, reproducibility, and limit of detection studies. The results from this study support the use of OncoKids for routine clinical testing of a wide variety of pediatric malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.